The introduction of immune-checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) has led to a paradigmatic change in the systemic treatment of HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.